Top 5 Articles From the Print Publication in 2023
Articles about upcoming approvals and Humira biosimilars were among those that garnered the most interest.
Articles about upcoming approvals and Humira biosimilars were among those that garnered the most interest.
Here are the five articles published in the print publication of Managed Healthcare Executive that had the most pageviews when they were posted on the MHE website.
4 Important Approvals Expected This Year
The approval of Mounjaro (tirzepatide) for weight loss could be a tipping point for weight-loss drugs. [The weight-loss version of tirzepatide is being sold under the brand-name Zepbound.]
’Tis the Year of the Humira Biosimilars
As many as 10 Humira biosimilars [it wound up being
The List of PBM Formulary Exclusions Got Longer in 2023
Pharmacy benefit managers say they exclude high-cost drugs and have alternatives on their formularies. Critics say exclusions narrow patient options and may put effective medication financially out of reach.
Why States Are Allowing Pharmacies to Dispense Returned Oncology Drugs
Repositories of donated drugs in 13 states are redistributing oncology medications to those in need.
Antibody-Drug Conjugates Find and Kill Cancer Cells
Three ADCs are in late-stage trials as treatments for patients with non-small cell lung cancer.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
